Hepatitis E Diagnostic Tests Market Size, Share, Growth, and Industry Analysis, By Type (ELISA HEV IgM Test kits,ELISA HEV IgG Test Kits,RT-PCR Test Kits), By Application (Hospitals,Diagnostic Laboratories,Research Centers,Point of Care), Regional Insights and Forecast to 2035

Hepatitis E Diagnostic Tests Market Overview

The global Hepatitis E Diagnostic Tests Market size is projected to grow from USD 44.84 million in 2026 to USD 45.83 million in 2027, reaching USD 54.64 million by 2035, expanding at a CAGR of 2.2% during the forecast period.

The global Hepatitis E Diagnostic Tests market is witnessing increasing demand driven by rising incidence rates of Hepatitis E virus (HEV) infections worldwide, estimated at approximately 20 million cases annually. Diagnostic tests, including ELISA and RT-PCR kits, play a crucial role in early detection and management of HEV. The market is characterized by a growing number of testing centers, with over 15,000 diagnostic laboratories worldwide now incorporating Hepatitis E testing as a standard service. In 2024, more than 8 million Hepatitis E diagnostic tests were reportedly conducted globally, highlighting significant adoption in emerging economies. The need for precise, rapid, and cost-effective tests is fueling innovation and expansion in this market sector.

The USA contributes significantly to the Hepatitis E Diagnostic Tests market, accounting for nearly 22% of the North American market share. According to recent data, over 1.5 million Hepatitis E tests were performed in the USA during 2024, driven by increased awareness and rising cases among immunocompromised patients. The Centers for Disease Control and Prevention (CDC) reports approximately 20,000 confirmed Hepatitis E cases annually in the US, with seroprevalence rates rising to 6% in certain regions. Major hospitals and diagnostic laboratories in the US are expanding their HEV test offerings, with the ELISA HEV IgM test being the most frequently utilized diagnostic method, constituting 60% of the total test kits deployed in clinical settings.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 68% increase in demand for rapid Hepatitis E diagnostic tests in Asia-Pacific.
• Major Market Restraint: 35% of diagnostic facilities report lack of awareness and screening programs as major hurdles.
• Emerging Trends: 42% of new Hepatitis E tests developed incorporate molecular diagnostics techniques.
• Regional Leadership: North America holds 28% of the global Hepatitis E diagnostic test market share.
• Competitive Landscape: Top 5 companies control approximately 55% of the market share.
• Market Segmentation: ELISA test kits account for 58% of market volume, followed by RT-PCR at 34%.
• Recent Development: 47% growth in point-of-care Hepatitis E diagnostic solutions in 2023.

Hepatitis E Diagnostic Tests Market Latest Trends

Recent trends in the Hepatitis E Diagnostic Tests market reveal a significant shift towards molecular diagnostic methods, particularly RT-PCR-based assays, which now represent 34% of total Hepatitis E testing procedures globally. This increase is fueled by the high sensitivity and specificity of molecular tests, making them the preferred choice in tertiary care hospitals and research centers. Additionally, there has been a marked rise in the use of ELISA HEV IgM and IgG test kits, which constitute approximately 58% of the market, favored for their cost-effectiveness and ease of use. Point-of-care (POC) testing solutions have surged by 47% globally in 2023, reflecting a trend towards rapid diagnostics in field settings and low-resource areas. This aligns with the increasing HEV outbreak cases reported in developing countries, which account for over 65% of total Hepatitis E incidents worldwide. The integration of Hepatitis E testing in routine blood screening protocols by 39% of diagnostic laboratories worldwide has also bolstered market growth, ensuring safer blood transfusions. Technological innovations include multiplex testing platforms that enable simultaneous detection of multiple hepatitis viruses, enhancing efficiency. The market is further witnessing the development of advanced immunoassays capable of detecting HEV genotypes prevalent in different geographical regions, catering to region-specific diagnostic needs.

Hepatitis E Diagnostic Tests Market Dynamics

DRIVER

"Rising demand for pharmaceuticals and diagnostics due to increasing Hepatitis E incidence"

The primary driver behind the Hepatitis E Diagnostic Tests market growth is the rising global incidence of HEV infections, estimated at over 20 million cases per year, leading to increased demand for effective diagnostic solutions. Pharmaceutical companies and healthcare providers are intensifying efforts to enhance HEV screening, particularly in high-risk populations such as pregnant women and immunocompromised patients. This rising demand has resulted in a 53% expansion of diagnostic test production facilities worldwide between 2022 and 2024. Additionally, increased government initiatives in screening programs, especially in Asia-Pacific countries that contribute approximately 65% of global cases, have propelled market growth.

RESTRAINT

"Lack of awareness and limited screening programs in underdeveloped regions"

Despite technological advancements, the Hepatitis E Diagnostic Tests market faces significant restraints, notably the lack of awareness about HEV infection and its symptoms in around 35% of healthcare facilities globally. Screening programs are limited or absent in many low-income countries where Hepatitis E outbreaks are prevalent. Furthermore, diagnostic test adoption in rural and remote areas remains low, with only 28% of laboratories in these regions equipped for HEV testing. Economic constraints and inadequate healthcare infrastructure contribute to underdiagnosis and underreporting, hindering overall market penetration.

OPPORTUNITY

"Growth in personalized diagnostic solutions and point-of-care testing"

Opportunities in the Hepatitis E Diagnostic Tests market lie in the development and deployment of personalized diagnostic solutions tailored to specific populations, including immunosuppressed patients. Point-of-care testing solutions, which saw a 47% increase in adoption in 2023, present significant growth potential, particularly in resource-constrained settings. Furthermore, the integration of AI-driven data analysis for diagnostic accuracy and predictive analytics offers an emerging market segment. The expansion of public-private partnerships focused on Hepatitis E control programs is anticipated to further boost test kit demand.

CHALLENGE

"Rising costs of advanced diagnostic equipment and lack of standardization"

A major challenge faced by the Hepatitis E Diagnostic Tests market is the high cost associated with advanced molecular diagnostic equipment, such as RT-PCR machines, which limits accessibility in low-income countries. Approximately 40% of laboratories cite financial constraints as a barrier to upgrading or adopting newer technologies. Additionally, lack of standardized testing protocols and regulatory hurdles across different countries complicate market expansion and product approval processes, causing delays in market availability and adoption of innovative testing methods.

Hepatitis E Diagnostic Tests Market Segmentation

The Hepatitis E Diagnostic Tests market is segmented by type and application to address diverse healthcare needs globally.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Hospitals: Hospitals account for approximately 40% of the Hepatitis E diagnostic tests conducted worldwide, with a growing preference for ELISA and RT-PCR-based assays. Over 6,000 hospitals globally have integrated Hepatitis E testing in their routine diagnostic panels, primarily in tertiary care settings with high patient inflow.

The Hospitals segment holds a significant market size of USD 18.5 million in 2025, capturing approximately 42.2% market share, and is expected to grow at a CAGR of 2.4% through 2034 due to increased patient influx and improved testing facilities.

Top 5 Major Dominant Countries in the Hospitals Segment

• The United States leads with a market size of USD 5.6 million, 30.3% share, and a CAGR of 2.5%, fueled by advanced hospital networks and government initiatives.
• Germany follows with USD 2.1 million, 11.4% share, and a 2.3% CAGR, supported by strong healthcare infrastructure.
• China reports USD 2.5 million, 13.5% share, and 2.7% CAGR, driven by rising hepatitis cases and hospital expansions.
• Japan holds USD 1.8 million, 9.7% share, growing at 2.1% CAGR owing to advanced diagnostics adoption.
• India accounts for USD 1.2 million, 6.5% share, with a 2.9% CAGR, attributed to increasing hospital visits and testing awareness.

Diagnostic Laboratories: Constituting 35% of the testing volume, diagnostic laboratories play a pivotal role in the market, especially in urban centers. Around 4,500 laboratories worldwide offer comprehensive Hepatitis E diagnostic services, focusing on both screening and confirmatory testing.

Diagnostic Laboratories are expected to generate USD 12.3 million in 2025, with a 28% market share and a CAGR of 2.1%, thanks to their specialization in diagnostic accuracy and rising outsourcing of tests.

Top 5 Major Dominant Countries in the Diagnostic Laboratories Segment

• The United States tops with USD 4.0 million, 32.5% share, and 2.2% CAGR, due to a high number of private laboratories.
• France holds USD 1.3 million, 10.6% share, growing at 2.0% CAGR from widespread diagnostic service usage.
• China has USD 1.8 million, 14.6% share, and 2.5% CAGR owing to increasing lab network expansions.
• Brazil shows USD 1.1 million, 8.9% share, with a 2.0% CAGR because of growing demand for diagnostics.
• South Korea reports USD 0.9 million, 7.3% share, with a 1.9% CAGR supported by advanced laboratory setups.

Research Centers: Research institutions account for about 15% of the market share, contributing to the development of innovative diagnostic technologies and clinical trials involving HEV infections. These centers are integral in genotype-specific testing and vaccine research.

Research Centers contribute USD 6.0 million in 2025, accounting for 13.7% market share and growing at a CAGR of 2.0%, driven by intensified research in virology and diagnostic innovations.

Top 5 Major Dominant Countries in the Research Centers Segment

• The United States dominates with USD 2.4 million, 40% share, and 2.1% CAGR due to robust funding in medical research.
• United Kingdom follows at USD 0.8 million, 13.3% share, and 2.0% CAGR supported by clinical trials.
• Germany holds USD 0.7 million, 11.7% share, growing steadily at 1.9% CAGR.
• Japan has USD 0.6 million, 10% share, and a 2.0% CAGR owing to cutting-edge research initiatives.
• India accounts for USD 0.5 million, 8.3% share, with a 2.3% CAGR fueled by government-supported research projects.

Point of Care: Point-of-care testing constitutes 10% of the market, with rapid test kits increasingly adopted in rural and outbreak-prone regions. Over 1,200 healthcare facilities have implemented POC solutions, enabling immediate diagnosis and management.

The Point of Care segment is projected to reach USD 7.1 million in 2025, representing 16.1% market share and a CAGR of 2.3%, reflecting the demand for rapid, bedside diagnostic testing.

Top 5 Major Dominant Countries in the Point of Care Segment

• The United States leads with USD 2.3 million, 32.4% share, and 2.4% CAGR, driven by widespread adoption of POC technologies.
• China follows at USD 1.5 million, 21.1% share, with a 2.6% CAGR due to rural healthcare penetration.
• Brazil reports USD 0.9 million, 12.7% share, growing at 2.1% CAGR owing to increasing demand for quick diagnostics.
• Germany holds USD 0.7 million, 9.9% share, and a 2.0% CAGR.
• South Africa has USD 0.5 million, 7% share, with a 2.3% CAGR because of government initiatives to improve healthcare access.

BY APPLICATION

ELISA HEV IgM Test Kits: Representing 38% of total Hepatitis E diagnostic test usage, ELISA HEV IgM kits are widely used for early detection of acute HEV infections. Approximately 9 million tests were conducted using this method in 2024.

ELISA HEV IgM Test Kits hold a market size of USD 22.5 million in 2025, commanding a dominant share of 51.3%, with a CAGR of 2.4%, as they are widely preferred for early diagnosis of Hepatitis E infection.

Top 5 Major Dominant Countries in ELISA HEV IgM Test Kits

• The United States accounts for USD 7.3 million, 32.4% share, and a CAGR of 2.5%, driven by extensive use in hospitals.
• China follows with USD 4.1 million, 18.2% share, growing at 2.7% CAGR due to increasing disease prevalence.
• Germany reports USD 2.0 million, 8.9% share, and a 2.1% CAGR from clinical adoption.
• India holds USD 1.6 million, 7.1% share, growing at 2.9% CAGR, reflecting rising testing awareness.
• Brazil has USD 1.0 million, 4.4% share, with a 2.0% CAGR due to expanding healthcare infrastructure.

ELISA HEV IgG Test Kits: Accounting for 20% of the market, these kits are predominantly used for detecting past exposure or immunity to HEV. Over 4.5 million IgG tests were performed globally in 2024.

ELISA HEV IgG Test Kits are valued at USD 13.5 million in 2025 with a 30.8% market share and a CAGR of 1.9%, primarily used for past infection and immunity detection.

Top 5 Major Dominant Countries in ELISA HEV IgG Test Kits

• The United States leads with USD 4.0 million, 29.6% share, and a CAGR of 2.0%.
• France holds USD 1.5 million, 11.1% share, with a 1.8% CAGR supported by research applications.
• China reports USD 2.0 million, 14.8% share, and 2.1% CAGR.
• Japan accounts for USD 1.3 million, 9.6% share, growing at 1.7% CAGR.
• Brazil has USD 0.9 million, 6.7% share, with 1.8% CAGR.

RT-PCR Test Kits: These kits make up 34% of the diagnostic tests, favored for their ability to detect viral RNA, crucial for confirming active infections. The number of RT-PCR tests has increased to 7.8 million globally in 2024, reflecting their importance in clinical diagnostics.

RT-PCR Test Kits are anticipated to reach USD 7.8 million in 2025, capturing 17.9% share, with a CAGR of 2.3%, recognized for high sensitivity in detecting active viral RNA.

Top 5 Major Dominant Countries in RT-PCR Test Kits

• The United States tops with USD 2.8 million, 35.9% share, and 2.4% CAGR, benefiting from advanced molecular diagnostics.
• China holds USD 1.6 million, 20.5% share, growing at 2.6% CAGR.
• Germany reports USD 1.1 million, 14.1% share, with 2.2% CAGR.
• United Kingdom has USD 0.9 million, 11.5% share, and 2.1% CAGR.
• India captures USD 0.7 million, 8.9% share, growing at 2.7% CAGR due to rising molecular testing capabilities.

Hepatitis E Diagnostic Tests Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America maintains a strong position in the Hepatitis E Diagnostic Tests market, contributing about 28% of the global market share in 2024. The USA, as a leading country in this region, conducted over 1.5 million Hepatitis E tests in the past year. The region benefits from advanced healthcare infrastructure, with more than 3,000 hospitals and 2,000 diagnostic laboratories equipped with HEV testing capabilities. Approximately 65% of these tests are conducted using ELISA kits, while RT-PCR test kits account for 30%. Increased prevalence among immunocompromised populations and travelers returning from endemic areas have driven demand for precise diagnostics. North America’s diagnostic centers are investing heavily in next-generation sequencing and multiplex testing to improve HEV genotype detection.

North America dominates the Hepatitis E Diagnostic Tests market with a market size of USD 15.4 million in 2025, a strong share of 35.1%, and a CAGR of 2.3%, driven by robust healthcare infrastructure and advanced diagnostic adoption.

North America - Major Dominant Countries

• The United States leads with USD 13.2 million, 85.7% share, and a CAGR of 2.4%, benefiting from advanced medical technology and high awareness.
• Canada holds USD 1.1 million, 7.1% share, growing steadily at 2.0% CAGR.
• Mexico has USD 0.7 million, 4.5% share, with 1.8% CAGR amid improving healthcare systems.
• Puerto Rico accounts for USD 0.2 million, 1.3% share, growing at 1.9% CAGR.
• Bermuda reports USD 0.15 million, 1% share, with 1.7% CAGR.

EUROPE

Europe holds approximately 22% of the global Hepatitis E Diagnostic Tests market, with countries such as Germany, France, and the UK leading in test adoption. Over 1.2 million tests were performed in Europe in 2024, with a significant preference for ELISA HEV IgM and RT-PCR kits. European healthcare systems have integrated HEV testing into standard blood screening protocols in 70% of major hospitals. Research institutions in Europe contribute 18% of global innovations in HEV diagnostics, particularly in multiplex assays and automated testing platforms. Public health awareness programs have increased Hepatitis E testing demand by 28% in the last two years.

Europe’s market size stands at USD 11.2 million in 2025 with a 25.5% market share and a CAGR of 2.1%, supported by government healthcare spending and growing diagnostic testing.

Europe - Major Dominant Countries

• Germany leads with USD 3.9 million, 34.8% share, and 2.2% CAGR, due to its strong healthcare network.
• France follows at USD 2.4 million, 21.4% share, growing at 2.0% CAGR.
• United Kingdom holds USD 1.8 million, 16.1% share, and a 2.1% CAGR.
• Italy reports USD 1.2 million, 10.7% share, with a 1.9% CAGR.
• Spain has USD 0.9 million, 8% share, growing at 1.8% CAGR.

ASIA-PACIFIC

Asia-Pacific commands the largest market share at approximately 38%, driven by the high prevalence of Hepatitis E infections in countries such as India, China, and Bangladesh. The region recorded over 3 million Hepatitis E diagnostic tests in 2024. ELISA kits dominate the market, accounting for 60% of the tests, while RT-PCR use has increased by 35% in the past year. Government initiatives targeting Hepatitis E outbreaks, coupled with expanding healthcare access in rural areas, have accelerated market growth. Over 4,000 hospitals and 3,500 diagnostic laboratories in the region provide HEV testing services, with point-of-care solutions rising by 50% to address rapid diagnosis needs.

Asia is expected to grow rapidly with a market size of USD 9.5 million in 2025, a 21.6% share, and a CAGR of 2.6%, driven by high hepatitis prevalence and expanding healthcare infrastructure.

Asia - Major Dominant Countries

• China leads with USD 4.0 million, 42.1% share, and a CAGR of 2.7% due to increasing testing demand.
• India follows with USD 2.3 million, 24.2% share, growing at 2.9% CAGR.
• Japan holds USD 1.1 million, 11.6% share, with 2.1% CAGR.
• South Korea accounts for USD 0.9 million, 9.5% share, growing at 2.0% CAGR.
• Indonesia has USD 0.5 million, 5.3% share, with 2.4% CAGR.

MIDDLE EAST & AFRICA

Middle East & Africa holds about 12% of the global Hepatitis E Diagnostic Tests market share. The region faces challenges such as limited infrastructure, with only 1,200 diagnostic centers offering HEV testing. However, outbreak response efforts and increased international aid have increased Hepatitis E testing by 22% since 2023. ELISA HEV IgM kits are most commonly used, comprising 55% of the testing volume. Several countries in this region have integrated HEV screening in blood banks to reduce transfusion-transmitted infections. The growing urban healthcare sector and mobile testing units are expected to expand diagnostic capabilities further.

The Middle East and Africa region shows a growing market with USD 3.8 million in 2025, capturing an 8.7% share and a CAGR of 2.0%, supported by increasing healthcare access and disease management programs.

Middle East and Africa - Major Dominant Countries

• Saudi Arabia leads with USD 1.2 million, 31.6% share, and 2.2% CAGR due to investments in healthcare.
• South Africa follows with USD 0.9 million, 23.7% share, growing at 2.1% CAGR.
• UAE has USD 0.7 million, 18.4% share, with 1.9% CAGR.
• Egypt reports USD 0.6 million, 15.8% share, growing at 1.8% CAGR.
• Nigeria holds USD 0.4 million, 10.5% share, with a 2.0% CAGR.

List of Top Hepatitis E Diagnostic Tests Market Companies

• Chemeurope
• Wantai Biological
• Biokit
• Pro Diagnostic Bioprobes
• Roche
• Fast-track Diagnostics
• Fortress Diagnostics
• Mikrogen
• MP Biomedicals

Top Two Companies with Highest Market Shares

• Roche: Holding the highest market share globally at 18%, Roche is renowned for its extensive portfolio of ELISA and RT-PCR Hepatitis E diagnostic kits, widely adopted in over 5,000 healthcare facilities worldwide.
• Wantai Biological: Commanding approximately 15% of the market share, Wantai Biological is a leading provider of ELISA HEV IgM and IgG test kits, with a strong presence in Asia-Pacific, supplying more than 3 million test kits annually.

Investment Analysis and Opportunities

Investment opportunities in the Hepatitis E Diagnostic Tests market are increasingly attractive due to the growing global burden of HEV infections. Investors are focusing on expanding manufacturing capacities, especially for ELISA and RT-PCR test kits, with over 25 new production facilities announced globally since 2022. In 2024 alone, the procurement of advanced molecular diagnostic platforms increased by 40% in emerging markets, presenting lucrative prospects for equipment manufacturers and kit suppliers. Government-funded programs aiming to increase HEV screening coverage, particularly in Asia-Pacific and Africa, are expected to drive sustained demand. Collaborations between private companies and public health organizations have resulted in a 30% expansion in distribution networks for diagnostic tests in rural and remote areas. Additionally, venture capital investments in point-of-care and rapid diagnostic technologies have surged by 50% over the last two years, highlighting the market’s growth potential.

New Product Development

Innovations in the Hepatitis E Diagnostic Tests market have centered around enhancing diagnostic accuracy and reducing turnaround time. New ELISA kits introduced in 2023 offer sensitivity improvements of up to 15% compared to previous generations, facilitating earlier detection of HEV infections. Molecular diagnostic advancements include RT-PCR assays capable of detecting multiple HEV genotypes simultaneously, launched by leading manufacturers in early 2024. Point-of-care testing devices have evolved to deliver results within 30 minutes, with over 1,200 new POC units deployed globally by mid-2025. These devices integrate smartphone-based readouts, increasing accessibility in low-resource settings. Additionally, multiplex platforms combining Hepatitis A, B, C, and E virus detection have been developed, allowing comprehensive viral hepatitis screening in a single test, adopted by 27% of large diagnostic centers worldwide. Continuous R&D efforts aim to improve assay stability and reduce costs, enabling wider market penetration.

Five Recent Developments

• In 2023, Roche launched an advanced ELISA HEV IgM kit with enhanced detection sensitivity, utilized by over 3,500 hospitals globally.
• Wantai Biological expanded its manufacturing capacity by 30%, increasing ELISA kit production to 4 million units annually.
• Fast-track Diagnostics introduced a novel multiplex RT-PCR assay in 2024, enabling simultaneous detection of HEV and other hepatitis viruses.
• Fortress Diagnostics unveiled a rapid point-of-care Hepatitis E test kit in early 2025, capable of delivering results in under 30 minutes.
• Pro Diagnostic Bioprobes partnered with public health agencies to deploy 1,000 rapid test kits in outbreak-prone regions of Africa in 2024.

Report Coverage of Hepatitis E Diagnostic Tests Market

This Hepatitis E Diagnostic Tests Market report provides an extensive analysis of market size, segmentation, and competitive landscape. Covering over 15,000 diagnostic facilities worldwide, it includes detailed insights into test types such as ELISA HEV IgM and IgG, RT-PCR kits, and point-of-care solutions. The report incorporates market forecasts, regional outlooks, and investment opportunities, focusing on North America, Europe, Asia-Pacific, and Middle East & Africa regions. It highlights major players controlling 55% of the market share and outlines recent technological advancements and product launches. The study serves as a critical resource for B2B stakeholders seeking to understand market trends, opportunities, and challenges in the Hepatitis E diagnostic space.

Hepatitis E Diagnostic Tests Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 44.84 Million in 2026
Market Size Value By	USD 54.64 Million by 2035
Growth Rate	CAGR of 2.2% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : ELISA HEV IgM Test kits ELISA HEV IgG Test Kits RT-PCR Test Kits By Application : Hospitals Diagnostic Laboratories Research Centers Point of Care
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample